L&C Professional Medical Research Institute Trials

L&C Professional Medical Research Institute	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Miller, William

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

TACTiC, NCT04964544: Technology-Assisted Cholesterol Trial in Consumers

Completed

1196

5 mg rosuvastatin calcium with a Web App (combination product), Crestor 5 mg

AstraZeneca, Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, The Cleveland Clinic

High Cholesterol

03/23

Shah, Anil

NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting

8600

Naltrexone-Bupropion (NB) Combination, Placebo

Currax Pharmaceuticals

Obesity

01/29

07/29

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated

335

Europe, Canada, Japan, US, RoW

LY3540378, Placebo

Eli Lilly and Company

Heart Failure, Heart Failure With Preserved Ejection Fraction

01/25

Garcia

NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting

1710

LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

Insud Pharma, Chemo Research

Change in Bone Mineral Density, Bone Loss

07/26

03/27

NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting

320

Europe, Canada, US, RoW

sunvozertinib, Pemetrexed+carboplatin

Dizal Pharmaceuticals

Non-small Cell Lung Cancer

02/26

10/27

PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting

9541

Europe, Canada, Japan, US, RoW

Obicetrapib, Placebo

NewAmsterdam Pharma, Monash University

Atherosclerotic Cardiovascular Disease

11/26

Garcia, Liagnys

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

Hanabergh, Enrique

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

Kimmel, Bonnie S

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting

360

Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo

Eli Lilly and Company, Regeneron Pharmaceuticals

Obesity

12/25

04/26

NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Recruiting

240

Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

04/26

01/27

NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Active, not recruiting

180

Canada, Japan, US, RoW

Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

10/26

01/27

Morrison, Volrick

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting

14013

Europe, Canada, US, RoW

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml

Novartis Pharmaceuticals

Primary Prevention of Atherosclerotic Cardiovascular Disease

04/29

NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Active, not recruiting

180

Canada, Japan, US, RoW

Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

10/26

01/27

NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting

N/A

800

Rapid point of care test to detect host immune response in ARI, Fingerstick test

Lumos Diagnostics, Biomedical Advanced Research and Development Authority

Acute Respiratory Infections (ARIs)

05/25

06/25

Perez, Maylen

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Miller, William

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

TACTiC, NCT04964544: Technology-Assisted Cholesterol Trial in Consumers

Completed

1196

5 mg rosuvastatin calcium with a Web App (combination product), Crestor 5 mg

AstraZeneca, Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, The Cleveland Clinic

High Cholesterol

03/23

Shah, Anil

NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting

8600

Naltrexone-Bupropion (NB) Combination, Placebo

Currax Pharmaceuticals

Obesity

01/29

07/29

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated

335

Europe, Canada, Japan, US, RoW

LY3540378, Placebo

Eli Lilly and Company

Heart Failure, Heart Failure With Preserved Ejection Fraction

01/25

Garcia

NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting

1710

LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

Insud Pharma, Chemo Research

Change in Bone Mineral Density, Bone Loss

07/26

03/27

NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting

320

Europe, Canada, US, RoW

sunvozertinib, Pemetrexed+carboplatin

Dizal Pharmaceuticals

Non-small Cell Lung Cancer

02/26

10/27

PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting

9541

Europe, Canada, Japan, US, RoW

Obicetrapib, Placebo

NewAmsterdam Pharma, Monash University

Atherosclerotic Cardiovascular Disease

11/26

Garcia, Liagnys

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

Hanabergh, Enrique

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

Kimmel, Bonnie S

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting

360

Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo

Eli Lilly and Company, Regeneron Pharmaceuticals

Obesity

12/25

04/26

NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Recruiting

240

Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

04/26

01/27

NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Active, not recruiting

180

Canada, Japan, US, RoW

Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

10/26

01/27

Morrison, Volrick

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting

14013

Europe, Canada, US, RoW

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml

Novartis Pharmaceuticals

Primary Prevention of Atherosclerotic Cardiovascular Disease

04/29

NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Active, not recruiting

180

Canada, Japan, US, RoW

Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo

Eli Lilly and Company

Obesity, Overweight

10/26

01/27

NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting

N/A

800

Rapid point of care test to detect host immune response in ARI, Fingerstick test

Lumos Diagnostics, Biomedical Advanced Research and Development Authority

Acute Respiratory Infections (ARIs)

05/25

06/25

Perez, Maylen

NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting

Spinosad Topical, Natroba, benzyl alcohol

Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix

Scabies

11/25

03/26



	Diseases Companies Products Productz Mechanisms of Action Sites